Urokinase clinical trials
Urokinase is named as an intervention in 3 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Nanjing First Hospital, Nanjing Medical University (1). The most-studied condition is Pulmonary Embolism.
Where Urokinase is approved
All regulators →Of the three regulators tracked here, the first to approve Urokinase was the US, on 16 Jan 1978.
- 1 EU orphan designation, most recently for treatment of thrombotic thrombocytopenic purpura (25 Jul 2024, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Urokinase works
All drug targets →- Urokinase-type plasminogen activator exogenous protein Exogenous proteinTarget: PLAU plasminogen activator, urokinaseChEMBL only
- Diabetic footPhase 3
- EmpyemaPhase 3
- Ischemic strokePhase 3
- Stroke disorderPhase 3
- Congestive heart failurePhase 2/3
- Pulmonary embolismPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201420, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Urokinase
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Urokinase
- ChEMBL
- CHEMBL1201420
- DrugBank
- DB00013
- CAS number
- 9039-53-6
- FDA UNII
- 83G67E21XI
- Wikidata
- Q110969665
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Urokinase
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)
NCT06284642 · ClinicalTrials.gov ↗ · Aneurysmal Subarachnoid Hemorrhage
|
Phase 4 | Recruiting | Second Affiliated Hospital of Nanchang University | China |
|
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
NCT06194968 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
|
Observational | Recruiting | The First Affiliated Hospital of Zhengzhou University | China |
|
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
NCT07603700 · ClinicalTrials.gov ↗ · Pulmonary Embolism, Venous Thromboembolism
|
Observational | Not yet open | Nanjing First Hospital, Nanjing Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Urokinase
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Nanjing First Hospital, Nanjing Medical University | 1 |
| The First Affiliated Hospital of Zhengzhou University | 1 |
| Second Affiliated Hospital of Nanchang University | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Urokinase trials
How many clinical trials are testing Urokinase?
3 current trials in our China register name Urokinase as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Urokinase trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Urokinase clinical trials?
Nanjing First Hospital, Nanjing Medical University (1), The First Affiliated Hospital of Zhengzhou University (1) and Second Affiliated Hospital of Nanchang University (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Urokinase works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Urokinase works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Urokinase (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.